These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 28580631)

  • 21. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM; Silverman ED; McCrindle BW; Yeung RS
    J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary adjunctive corticosteroid therapy is associated with improved outcomes for patients with Kawasaki disease with coronary artery aneurysms at diagnosis.
    Friedman KG; Gauvreau K; Baker A; Son MB; Sundel R; Dionne A; Giorgio T; De Ferranti S; Newburger JW
    Arch Dis Child; 2021 Mar; 106(3):247-252. PubMed ID: 32943389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjunctive therapies for Kawasaki disease.
    Campbell AJ; Burns JC
    J Infect; 2016 Jul; 72 Suppl():S1-5. PubMed ID: 27241708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aspirin Dose in Kawasaki Disease: The Ongoing Battle.
    Dhanrajani A; Chan M; Pau S; Ellsworth J; Petty R; Guzman J
    Arthritis Care Res (Hoboken); 2018 Oct; 70(10):1536-1540. PubMed ID: 29287309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidemiologic study of Kawasaki disease and cases resistant to IVIG therapy in Thailand.
    Durongpisitkul K; Sangtawesin C; Khongphatthanayopthin A; Panamonta M; Sopontammarak S; Sittiwangkul R; Pongpanich B
    Asian Pac J Allergy Immunol; 2006 Mar; 24(1):27-32. PubMed ID: 16913186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Kawasaki disease in children--9 years experience].
    Kowalczyk M; Kawalec W; Daszkowska-York J; Turska-Kmieć A; Brzezińska-Rajszys G; Sobielarska D; Ziółkowska L; Kościesza A; Jagiełłowicz D; Mirecka-Rola A
    Med Wieku Rozwoj; 2005; 9(2):179-93. PubMed ID: 16085959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis.
    Miyata K; Bainto EV; Sun X; Jain S; Dummer KB; Burns JC; Tremoulet AH
    Arch Dis Child; 2023 Oct; 108(10):833-838. PubMed ID: 37258054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
    Kuo HC; Lo MH; Hsieh KS; Guo MM; Huang YH
    PLoS One; 2015; 10(12):e0144603. PubMed ID: 26658843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting coronary aneurysms in Kawasaki disease.
    Gersony WM
    Am J Cardiol; 1998 May; 81(9):1162-4. PubMed ID: 9605060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early Appearance of Principal Symptoms of Kawasaki Disease is a Risk Factor for Intravenous Immunoglobulin Resistance.
    Tajima M; Shiozawa Y; Kagawa J
    Pediatr Cardiol; 2015 Aug; 36(6):1159-65. PubMed ID: 25753685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting IVIG resistance in UK Kawasaki disease.
    Davies S; Sutton N; Blackstock S; Gormley S; Hoggart CJ; Levin M; Herberg JA
    Arch Dis Child; 2015 Apr; 100(4):366-8. PubMed ID: 25670405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial).
    Tremoulet AH; Jain S; Kim S; Newburger J; Arditi M; Franco A; Best B; Burns JC
    Contemp Clin Trials; 2016 May; 48():70-5. PubMed ID: 27080929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A girl with extremely refractory Kawasaki disease: an instructive case with unusual course and outcome.
    Kossiva L; Karanassios E; Papadopoulos G; Karavanaki K
    Cardiol Young; 2012 Aug; 22(4):461-5. PubMed ID: 21933460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kawasaki Disease.
    Newburger JW; Takahashi M; Burns JC
    J Am Coll Cardiol; 2016 Apr; 67(14):1738-49. PubMed ID: 27056781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delayed Development of Coronary Artery Aneurysm in Patients with Kawasaki Disease Who Were Clinically Responsive to Immunoglobulin.
    Matsuoka R; Furuno K; Nanishi E; Onoyama S; Nagata H; Yamamura K; Sugitani Y; Kuraoka A; Mizuno Y; Sagawa K; Honjo S; Hara T; Ohga S
    J Pediatr; 2020 Dec; 227():224-230.e3. PubMed ID: 32810506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
    Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
    Lei WT; Chang LS; Zeng BY; Tu YK; Uehara R; Matsuoka YJ; Su KP; Lee PC; Cavalcante JL; Stubbs B; Lin PY; Wu YC; Hsu CW; Chen TY; Chen YW; Yeh PY; Sun CK; Tseng PT; Kao YH
    EBioMedicine; 2022 Apr; 78():103946. PubMed ID: 35306339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors of immunoglobulin resistance and coronary complications in children with Kawasaki disease.
    Berdej-Szczot E; Małecka-Tendera E; Gawlik T; Firek-Pędras M; Szydłowski L; Gawlik A
    Kardiol Pol; 2017; 75(3):261-266. PubMed ID: 27995598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immunoglobulin therapy].
    Ogata S; Ishii M
    Nihon Rinsho; 2014 Sep; 72(9):1617-22. PubMed ID: 25518412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Clinical Utility and Safety of a New Strategy for the Treatment of Refractory Kawasaki Disease.
    Ebato T; Ogata S; Ogihara Y; Fujimoto M; Kitagawa A; Takanashi M; Ishii M
    J Pediatr; 2017 Dec; 191():140-144. PubMed ID: 29173297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.